Marginal Zone Lymphoma
Showing 26 - 50 of 103
B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy Trial (CTX112)
Not yet recruiting
- B-cell Lymphoma
- +7 more
- CTX112
- (no location specified)
Dec 12, 2022
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, MDS Trial in Tucson (Bendamustine, Cyclophosphamide)
Recruiting
- Acute Lymphoblastic Leukemia
- +12 more
-
Tucson, ArizonaThe University of Arizona Cancer Center
Dec 13, 2022
Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (tafasitamab, rituximab, lenalidomide)
Recruiting
- Follicular Lymphoma
- Marginal Zone Lymphoma
- tafasitamab
- +3 more
-
Concord, California
- +255 more
Dec 1, 2022
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma Trial in Japan (epcoritamab
Recruiting
- Diffuse Large B Cell Lymphoma
- +5 more
- epcoritamab (monotherapy)
- +5 more
-
Chuo Ku, Japan
- +19 more
Nov 22, 2022
Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL) Trial in Augusta, Nashville, Houston
Recruiting
- Mantle Cell Lymphoma
- +9 more
- L-Bcl-2 antisense oligonucleotide
-
Augusta, Georgia
- +2 more
Nov 18, 2022
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial
Active, not recruiting
- Acute Leukemia
- +14 more
- Busulfan
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 18, 2022
Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)
Recruiting
- Relapsed/Refractory Follicular Lymphoma
- Marginal Zone Lymphoma
- Zanubrutinib
- +3 more
-
Westbury, New YorkClinical Research Alliance, Inc.
Nov 14, 2022
Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma Trial in United States (ADI-001, Fludarabine,
Recruiting
- Lymphoma, Follicular
- +5 more
- ADI-001
- +2 more
-
Stanford, California
- +6 more
Oct 19, 2022
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in Miami (Acalabrutinib,
Terminated
- Diffuse Large B Cell Lymphoma
- +3 more
- Acalabrutinib
- +4 more
-
Miami, FloridaUniversity of Miami
Aug 23, 2022
B-Cell Lymphoma, B Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma Trial in Pittsburgh (Chimeric Antigen Receptor
Recruiting
- B-Cell Lymphoma
- +8 more
- Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)
-
Pittsburgh, PennsylvaniaAHN Cancer Institute - West Penn Hospital
Aug 10, 2022
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Tumor, Chronic Lymphocytic Leukemia Trial in Rochester (Ibrutinib,
Withdrawn
- Asymptomatic COVID-19 Infection Laboratory-Confirmed
- +8 more
- Ibrutinib
- Quality-of-Life Assessment
-
Rochester, MinnesotaMayo Clinic in Rochester
Aug 2, 2022
Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Zandelisib, Rituximab, Bendamustine)
Recruiting
- Follicular Lymphoma (FL)
- +2 more
- Zandelisib
- +3 more
-
Tucson, Arizona
- +134 more
Jul 27, 2022
Follicular Lymphoma, Marginal Zone Lymphoma Trial in Italy, Spain, United States (EO2463, lenalidomide, rituximab)
Recruiting
- Follicular Lymphoma
- Marginal Zone Lymphoma
- EO2463
- +2 more
-
Boston, Massachusetts
- +9 more
Jul 26, 2022
DLBCL, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (Ublituximab, Umbralisib, Bendamustine)
Terminated
- Diffuse Large B-Cell Lymphoma
- +4 more
- Ublituximab
- +2 more
-
Birmingham, Alabama
- +167 more
Jul 20, 2022
Follicular Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma Trial in New Haven, New Brunswick, Providence (Mosunetuzumab,
Recruiting
- Follicular Lymphoma
- +2 more
-
New Haven, Connecticut
- +2 more
Jul 14, 2022
Marginal Zone Lymphoma Trial in Miami (Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg)
Recruiting
- Marginal Zone Lymphoma
- Loncastuximab tesirine 150 µg/Kg
- Loncastuximab tesirine 75µg/Kg
-
Miami, FloridaUniversity of Miami
Jul 12, 2022
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL) Trial in Milwaukee (8/12-Day
Recruiting
- Non Hodgkin Lymphoma (NHL)
- +6 more
- 8/12-Day Production of Car-T Cells
- +2 more
-
Milwaukee, WisconsinMedical College of Wisconsin and Froedtert Hospital
Jul 1, 2022
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma Trial in Worldwide (GEN3009, Epcoritamab)
Recruiting
- Diffuse Large B-cell Lymphoma
- +7 more
- GEN3009
- Epcoritamab
-
Tucson, Arizona
- +31 more
Jul 1, 2022
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma Trial in United States (Cirmtuzumab (2-16
Recruiting
- B-cell Chronic Lymphocytic Leukemia
- +3 more
- Cirmtuzumab (2-16 kg/mg) plus Ibrutinib
- +5 more
-
Duarte, California
- +12 more
Jun 16, 2022